$53.86▲ 1.84 (3.54%)
Real-time prices · US MarketsClean balance sheet with low leverage (0.4× debt-to-equity).
low return on equity (-31%).
Quality
1.6
Health
8.7
Growth
6.8
Valuation
6.9
Sentiment
6.8
Analyst Target
$83.52
▲ +55.1% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
-14.1×
next 12 months est.
Market Cap
$5.3B
market capitalization
Div Yield
—
dividend yield
Profit Margin
0.0%
net profit margin
Gross Margin
0.0%
revenue minus COGS
ROE
-31.2%
return on equity
Beta
1.70
vs S&P 500
52-Week Range
$42 — $78
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about CRISPR Therapeutics AG right now?
CRISPR Therapeutics AG's Q·Score is 5.9/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.4× debt-to-equity). Key area to monitor: low return on equity (-31%). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for CRSP?
The consensus price target for CRSP is $83.52, based on ratings from 21 Wall Street analysts. This is 55.1% above the current price of $53.86. Price targets are forward-looking estimates and not guarantees of future performance.
Is CRSP overvalued or undervalued?
CRISPR Therapeutics AG (CRSP) scores in line with sector averages on valuation metrics. The consensus analyst price target of $83.52 is 55% above the current price.
What is CRISPR Therapeutics AG's profit margin?
CRISPR Therapeutics AG has a net profit margin of 0.0%, indicating the company is currently operating at a net loss. Its gross margin stands at 0.0%, reflecting a more cost-intensive business model.
Is CRISPR Therapeutics AG's revenue growing?
CRISPR Therapeutics AG is reporting strong year-over-year growth of 68.6%.
How much debt does CRISPR Therapeutics AG have?
CRISPR Therapeutics AG has a debt-to-equity ratio of 0.43×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 17.96×, indicating comfortable short-term liquidity.